Evogene Ltd. (NASDAQ:EVGN – Get Free Report) was the target of a large growth in short interest in September. As of September 30th, there was short interest totaling 932,725 shares, a growth of 1,541.9% from the September 15th total of 56,809 shares. Based on an average daily trading volume, of 6,278,931 shares, the short-interest ratio is currently 0.1 days. Currently, 11.6% of the shares of the stock are short sold.
Evogene Stock Down 4.1%
Shares of EVGN opened at $0.38 on Friday. The business has a fifty day moving average of $0.52 and a 200 day moving average of $0.61. The company has a market cap of $3.33 million, a PE ratio of -0.42 and a beta of 1.44. Evogene has a 52-week low of $0.35 and a 52-week high of $1.49.
Analyst Ratings Changes
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Evogene in a research note on Friday, October 2nd. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock has an average rating of “Sell”.
Insider Buying and Selling at Evogene
In other Evogene news, Director Leon Recanati bought 460,000 shares of Evogene stock in a transaction dated Tuesday, August 11th. The shares were purchased at an average cost of $0.64 per share, for a total transaction of $294,400.00. Following the acquisition, the director directly owned 1,343,886 shares in the company, valued at approximately $860,087.04. This represents a 52.04% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 7.40% of the stock is currently owned by company insiders.
About Evogene
Evogene Ltd. is an Israel-based computational biology company that develops products and technologies for the life sciences and agriculture industries. Founded in 1999 and headquartered in Rehovot, Israel, the company uses its Computational Predictive Biology platform, which combines biological data, artificial intelligence and machine-learning tools to identify and develop novel biological products.
Evogene’s activities have included agricultural solutions such as crop-protection products, bio-stimulants and microbiome-based technologies.
See Also
- Five stocks we like better than Evogene
- Delta Air Lines Faces a Fuel Crisis—But There’s a Silver Lining
- Is Synopsys Back from the Dead? EDA Leader Inks Deals With Amazon and OpenAI
- MarketBeat Week in Review – 10/05 – 10/09
- Alphabet Introduces Gemini Agent—Can It Trigger a Breakout?
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.
